Stock Track | Recursion Pharmaceuticals Soars 7.93% in Pre-market on Strong Q4 Earnings Beat

Stock Track02-25 19:34

Recursion Pharmaceuticals, Inc. (RXRX) saw its stock price surge 7.93% in pre-market trading on Wednesday, following the release of its fourth-quarter financial results.

The biotechnology company reported Q4 operating revenue of $35.351 million, significantly exceeding the IBES estimate of $24.6 million. Additionally, Recursion's Q4 net loss of $108.124 million was narrower than the estimated loss of $131.1 million, indicating better-than-expected financial performance.

The positive earnings surprise, with both revenue and net income beating analyst expectations, appears to be driving investor optimism and the substantial pre-market price increase.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1155956762?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-25 19:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1155956762","market":"nz","top_or_hot":-1,"title":"Stock Track | Recursion Pharmaceuticals Soars 7.93% in Pre-market on Strong Q4 Earnings Beat","media":"Stock Track","content":"<p>Recursion Pharmaceuticals, Inc. (RXRX) saw its stock price surge 7.93% in pre-market trading on Wednesday, following the release of its fourth-quarter financial results.</p><p>The biotechnology company reported Q4 operating revenue of $35.351 million, significantly exceeding the IBES estimate of $24.6 million. Additionally, Recursion's Q4 net loss of $108.124 million was narrower than the estimated loss of $131.1 million, indicating better-than-expected financial performance.</p><p>The positive earnings surprise, with both revenue and net income beating analyst expectations, appears to be driving investor optimism and the substantial pre-market price increase.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Recursion Pharmaceuticals Soars 7.93% in Pre-market on Strong Q4 Earnings Beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Recursion Pharmaceuticals Soars 7.93% in Pre-market on Strong Q4 Earnings Beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-25 19:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Recursion Pharmaceuticals, Inc. (RXRX) saw its stock price surge 7.93% in pre-market trading on Wednesday, following the release of its fourth-quarter financial results.</p><p>The biotechnology company reported Q4 operating revenue of $35.351 million, significantly exceeding the IBES estimate of $24.6 million. Additionally, Recursion's Q4 net loss of $108.124 million was narrower than the estimated loss of $131.1 million, indicating better-than-expected financial performance.</p><p>The positive earnings surprise, with both revenue and net income beating analyst expectations, appears to be driving investor optimism and the substantial pre-market price increase.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RXRX","symbol_name":"Recursion Pharmaceuticals, Inc.","start_time":0,"source_url":"","article_id":"1155956762","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1155956762","pubTimestamp":1772019271,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Recursion Pharmaceuticals, Inc. (RXRX) saw its stock price surge 7.93% in pre-market trading on Wednesday, following the release of its fourth-quarter financial results.The biotechnology company...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RXRX":"Recursion Pharmaceuticals, Inc."},"translate_title":"个股追踪|Recursion Pharmaceuticals盘前飙升7.93%，因第四季度盈利强劲","themeId":"101ec87b89813fb9d95dbaf13286caff","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RXRX":1},"content_text":"Recursion Pharmaceuticals, Inc. (RXRX) saw its stock price surge 7.93% in pre-market trading on Wednesday, following the release of its fourth-quarter financial results.The biotechnology company reported Q4 operating revenue of $35.351 million, significantly exceeding the IBES estimate of $24.6 million. Additionally, Recursion's Q4 net loss of $108.124 million was narrower than the estimated loss of $131.1 million, indicating better-than-expected financial performance.The positive earnings surprise, with both revenue and net income beating analyst expectations, appears to be driving investor optimism and the substantial pre-market price increase.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1155956762","isCrawlerRequest":true}